Andrew Newland, chief executive of ANGLE PLC (), discusses with Proactive their co-marketing agreement with QIAGEN NV, a world-leading provider of molecular testing solutions.
The initial focus will be on prostate and breast cancer research applications.
The agreement will see both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE